Amicus Therapeutics Inc.
Amicus Therapeutics Announces Third Quarter 2024 Financial Results and Corporate Updates
Summary
On November 6, 2024, Amicus Therapeutics, Inc. announced its financial results for the third quarter of 2024, highlighting a 37% year-over-year increase in total revenue to $141.5 million. The company reported non-GAAP net income of $30.8 million for Q3 2024, reflecting strong demand for Galafold and the commercial launch of Pombiliti and Opfolda. Amicus also updated its full-year 2024 revenue guidance for Galafold to 16-18% growth and for Pombiliti + Opfolda to $69-71 million. Additionally, the company announced a settlement of the Galafold patent litigation with Teva Pharmaceuticals, which is a significant step for continued support of the Fabry community.
Profitelligence Alerts
Get alerts for FOLD
Be first to know when Amicus Therapeutics Inc. files with the SEC.
Filing Categories
Exhibits (2)
Advertisement
About Amicus Therapeutics Inc.
Amicus Therapeutics Inc. is a biopharmaceutical company dedicated to developing advanced therapies for rare and orphan diseases. Its primary focus is on genetic disorders, particularly lysosomal storage disorders and other diseases resulting from improper protein folding within cells. Amicus leverages its proprietary technology platforms to create drug candidates that address unmet medical needs, providing innovative solutions for complex conditions like Fabry disease and Pompe disease. The company's commitment to patient-centric innovation aims to enhance the quality of life for individuals facing challenging health diagnoses. Situated within the biotechnology sector, Amicus plays a significant role in advancing novel treatment options, thereby impacting healthcare markets and potentially transforming the standard of care for rare genetic diseases. Founded in 2002, the company harnesses cutting-edge research and collaborations to foster groundbreaking developments in the therapeutic landscape uniquely shaped by the complexities of rare diseases.
Official SEC Documents
Advertisement